Synthetic Biology Market Report 2026

The synthetic biology market size has grown exponentially in recent years. It will grow from $26.63 billion in 2025 to $32 billion in 2026 at a compound annual growth rate (CAGR) of 20.2%. The growth in the historic period can be attributed to advancements in genetic engineering techniques, expansion of academic and industrial research funding, growing availability of sequencing technologies, early commercialization of synthetic organisms, increasing collaboration between academia and industry.

The synthetic biology market size is expected to see rapid growth in the next few years. It will grow to $62.48 billion in 2030 at a compound annual growth rate (CAGR) of 18.2%. The growth in the forecast period can be attributed to increasing investments in bio-manufacturing, rising demand for sustainable chemicals and fuels, expansion of synthetic biology applications in healthcare, growing integration of ai-driven biological design, increasing regulatory clarity for engineered organisms. Major trends in the forecast period include increasing adoption of crispr-based gene editing, rising use of bioinformatics-driven design tools, expansion of synthetic gene construction platforms, growing focus on sustainable bio-based production, enhanced automation in biological engineering workflows.

The increasing investment in research and development is expected to drive the growth of the synthetic biology market in the coming years. Research and development (R&D) involves generating new knowledge, technologies, or products through systematic investigation, experimentation, and innovation to improve existing offerings or create new ones. Rising R&D investments are fueled by growing competition, the demand for innovation, technological advancements, and the need for businesses to adapt to evolving consumer preferences and market conditions. In synthetic biology, R&D investment is critical for advancing the field’s potential to create sustainable solutions in healthcare, agriculture, and environmental management by engineering biological systems and organisms for specific applications. For example, in 2023, according to the Office for National Statistics, a UK-based government agency, the UK government’s net spending on R&D increased to £17.4 billion ($22.1 billion), up from £16.1 billion ($20.45 billion) in 2022, representing an 8.2% increase. Therefore, rising R&D investment is propelling the growth of the synthetic biology market.

Key companies in the synthetic biology market are focusing on developing innovative offerings, such as custom solutions programs for design-build-test cycles, to accelerate tailored synthetic biology projects. A custom solutions program provides clients with a personalized service, allowing them to collaborate directly with experts to design, build, and test synthetic DNA constructs rather than relying on standard catalog products. For instance, in June 2025, Integrated DNA Technologies (IDT), a US-based biotechnology company, launched its Synthetic Biology Custom Solutions Program. This white-glove service gives customers access to IDT’s in-house scientists and engineers for tailored projects, including complex genes and non-standard DNA fragments. Key features include a dedicated team supporting design-build-test workflows, custom manufacturing in IDT’s 25,000-sq-ft synthetic biology facility, acceptance of diverse project types (e.g., high-yield non-standard gene fragments, genes >5 kb, multi-site cloning), and faster turnaround times by eliminating rigid high-throughput constraints. This program enables synthetic biology innovators to iterate more efficiently and overcome bottlenecks in their R&D efforts.

In March 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Ambrx, Inc., for an undisclosed amount. Through this acquisition, Johnson & Johnson aims to strengthen its biopharmaceutical pipeline, enhance its protein and peptide engineering capabilities, expand its portfolio of innovative therapeutics, and accelerate the development of next-generation biologics. Ambrx, Inc. is a US-based biotechnology company specializing in the design and development of site-specific protein and peptide therapeutics.

Major companies operating in the synthetic biology market are Thermo Fisher Scientific Inc, Danaher Corporation, Eurofins Scientific, Merck KGaA, Novozymes A/S, Agilent Technologies, New England Biolabs Inc, Precigen Inc, Amyris, Inc, Genscript Biotech Corporation, Codex Genetics, Cathay Biotech, Bota Biosciences, Bluepha, Spiber, OriCiro Genomics Inc, Provectus Algae, Puraffinity, Royal DSM NV, Colorifix, Phytoform Labs, Desktop Genetics, NanoSyrinx, Pulmobiotics S.L, EnginZyme, Chain Biotech, Nuclera Nucleics, Biosynthetics GmbH, Entelechon GmbH, Sloning BioTechnology GmbH, Prokarium Ltd, Synbio, Captor Therapeutics, Gero.ai, ARNA Genomics, Solvo Omixon, Soft flow, Algenol, Genomatica, Integrated DNA Technologies, Sana Biotechnology, Impossible Foods, Apeel Sciences, Twist Bioscience, Synlogic, Zymergen Inc, Ginkgo Bioworks, Codexis, Arzeda Corporation, Synthetic Genomics, Conagen, Dupont, Oxitec Ltd, Sentebiolab, GEEN Biotechnology Inc, Genbiotek Biosistem Laboratory Ltd.

North America was the largest region in the synthetic biology market in 2025. Western Europe was the second largest region in the global synthetic biology market share. The regions covered in the synthetic biology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the synthetic biology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the synthetic biology market by increasing costs of imported laboratory instruments, sequencing equipment, reagents, microfluidic devices, and advanced computing hardware. Research institutions and biotech companies in North America and Europe are most affected due to dependence on imported scientific equipment, while Asia-Pacific faces higher costs in export-oriented bioengineering products. These tariffs are raising research and development expenses and slowing equipment upgrades. However, they are also supporting local instrument manufacturing, regional reagent production, and domestic innovation ecosystems in synthetic biology.

The synthetic biology market research report is one of a series of new reports that provides synthetic biology market statistics, including synthetic biology industry global market size, regional shares, competitors with a synthetic biology market share, detailed synthetic biology market segments, market trends and opportunities, and any further data you may need to thrive in the synthetic biology industry. This synthetic biology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Synthetic biology is a branch of biological science that applies engineering principles to redesign organisms, giving them new functions and capabilities. It can be considered the deliberate and prescriptive stage of biology.

The main product types in synthetic biology include oligonucleotides, enzymes, cloning and assembly kits, xeno-nucleic acids (XNA), and chassis organisms. Oligonucleotides are short, single-stranded DNA sequences that can specifically suppress the expression of a particular protein when taken up by a cell. Key technologies in synthetic biology include nucleotide synthesis and sequencing, bioinformatics, microfluidics, and genetic engineering, which are applied across industries such as pharmaceuticals and diagnostics, chemicals, biofuels, bioplastics, and others.

The synthetic biology market includes revenue earned by synthetic compound, technology and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.